XBIO - Xenetic Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.8500
-0.1400 (-2.81%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.9900
Open4.8800
Bid4.8600 x 900
Ask4.9000 x 1000
Day's Range4.5700 - 4.9499
52 Week Range4.5700 - 55.2000
Volume175,360
Avg. Volume76,404
Market Cap4.221M
Beta (3Y Monthly)2.56
PE Ratio (TTM)N/A
EPS (TTM)-1.1470
Earnings DateNov 13, 2017 - Nov 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • ACCESSWIRE4 days ago

    Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering

    FRAMINGHAM, MA / ACCESSWIRE / July 17, 2019 / Xenetic Biosciences, Inc. (NASDAQ: XBIO) (“Xenetic” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced the pricing of an underwritten public offering of 2,300,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase up to 2,300,000 shares of the Company’s common stock. Each share of common stock is being sold together with one warrant to purchase one share of common stock at a combined price to the public of $6.50 per share and warrant.

  • Benzinga16 days ago

    Xenetic Biosciences Shares Surge After Biotech Prices Common Stock, Warrant Offering

    Nano-cap biotech Xenetic Biosciences Inc (NASDAQ: XBIO )'s stock was rallying Friday following an announcement concerning pricing for its previously announced offering of common stock and accompanying ...

  • ACCESSWIRE27 days ago

    Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

    FRAMINGHAM, MA / ACCESSWIRE / June 24, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), today announced it will effect a one-for-twelve reverse stock split of its issued and outstanding common stock. Pursuant to the Certificate of Change filed with the Secretary of State of the State of Nevada, the reverse stock split will be effective at 12:01 a.m., Eastern Time, on June 25, 2019. Xenetic expects that upon the opening of trading on June 25, 2019, its common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under the current trading symbol "XBIO" and the new CUSIP number 984015 503.

  • Introducing Xenetic Biosciences (NASDAQ:XBIO), The Stock That Collapsed 98%
    Simply Wall St.last month

    Introducing Xenetic Biosciences (NASDAQ:XBIO), The Stock That Collapsed 98%

    Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Anyone who held...

  • Benzinga2 months ago

    The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 13) BioSig Technologies Inc (NASDAQ: BSGM ) Milestone Pharmaceuticals ...

  • ACCESSWIRE2 months ago

    Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update

    FRAMINGHAM, MA / ACCESSWIRE / May 13, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its financial results for the quarter ended March 31, 2019 and provided a corporate update. With the anticipated closing of our acquisition of XCART, our differentiated CAR T platform technology, on track for this quarter, I believe Xenetic will be well positioned to drive momentum in the innovation and development of new oncology therapeutics where there remains significant unmet need," commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic.

  • ACCESSWIRE3 months ago

    Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Appointment of Guenther Koehne, M.D., Ph.D.

    FRAMINGHAM, MA / ACCESSWIRE / May 2, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today that it has appointed Guenther Koehne, M.D., Ph.D. to the Company's Scientific Advisory Board. Dr. Guenther Koehne is an internationally recognized cancer specialist and current Chief of Blood & Marrow Transplant and Hematologic Oncology at the Miami Cancer Institute.

  • ACCESSWIRE4 months ago

    Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update

    FRAMINGHAM, MA / ACCESSWIRE / April 1, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its financial results for the year ended December 31, 2018. Xenetic also provided a corporate update and reviewed plans related to the Company's recently announced agreement to acquire a novel CAR T ("Chimeric Antigen Receptor T Cell") platform technology, called "XCART", as well as its oncology therapeutic XBIO-101 (sodium cridanimod), a small-molecule immunomodulator and interferon inducer which, in preliminary studies has been shown to increase progesterone receptor ("PrR") expression in endometrial tumor tissue.

  • ACCESSWIRE5 months ago

    Xenetic Biosciences Announces Pricing of $3.1 Million Registered Direct Offering

    FRAMINGHAM, MA / ACCESSWIRE / March 5, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on the acquisition, research and development of novel oncology therapeutics, including next-generation cellular immunotherapies for difficult to treat cancers, including B-cell Lymphomas, as well as improved biologic drugs, today announced it has entered into a securities purchase agreement with a single accredited institutional investor to purchase approximately $3.1 million of the Company’s common stock (the "Common Stock") (or pre-funded warrants to purchase Common Stock in lieu thereof) in a registered direct offering (the "Offering") and warrants to purchase shares of Common Stock in a concurrent private placement. The combined purchase price for one share of Common Stock (or pre-funded warrants to purchase Common Stock in lieu thereof) and each warrant will be $2.00.

  • ACCESSWIRE5 months ago

    Xenetic Biosciences, Inc. (NASDAQ: XBIO) Announces Agreement to Acquire Innovative CAR T Technology Platform

    LEXINGTON, MA / ACCESSWIRE / March 4, 2019 / Xenetic Biosciences, Inc. (XBIO) ("Xenetic" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics, announced today its agreement to acquire the novel CAR T ("Chimeric Antigen Receptor T Cell") platform technology, called "XCART," a proximity-based screening platform capable of identifying CAR constructs that can target patient-specific tumor neoantigens, with a demonstrated proof of mechanism in B-cell Non-Hodgkin lymphomas. The XCART technology, developed by The Scripps Research Institute ("Scripps") in collaboration with the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, is believed to have the potential to significantly enhance the safety and efficacy of cell therapy for B-cell lymphomas by generating patient- and tumor-specific CAR T cells.

  • What Investors Should Know About Xenetic Biosciences Inc’s (NASDAQ:XBIO) Financial Strength
    Simply Wall St.8 months ago

    What Investors Should Know About Xenetic Biosciences Inc’s (NASDAQ:XBIO) Financial Strength

    Xenetic Biosciences Inc (NASDAQ:XBIO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is XBIO Read More...

  • Why Xenetic Biosciences Just Surged 28 Percent
    InvestorPlace11 months ago

    Why Xenetic Biosciences Just Surged 28 Percent

    Nanocap stocks are inherently risky in the stock market, but can certainly pay off for speculators when they go up. Xenetic Biosciences Inc. (NASDAQ:XBIO) surged 28%, up twofold from the $2 level the stock has been stuck at over the last year. At a closing price of $4.08 on Monday, Aug. 13, XBIO stock is still well below the $8.95 intraday high set in late-June.

  • ACCESSWIRE11 months ago

    Xenetic Biosciences Oncology Phase II Trial in Process, Pipeline Overview

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Xenetic Biosciences, Inc. (XBIO), a clinical-stage biopharmaceutical company. The company's lead investigational product candidate is oncology therapeutic XBIO-101 (sodium cridanimod) for the treatment of progesterone resistant endometrial cancer. In 2018, an estimated 63,000 cases of endometrial cancer will be diagnosed in the U.S., and an estimated 11,000 disease-associated deaths will occur.

  • ACCESSWIRE11 months ago

    Today’s Research Reports on Stocks to Watch: Xenetic Biosciences and Antares Pharma

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / There was no news to explain the sudden jump shares of Xenetic Biosciences saw in Monday’s trading session. Shares of Antares Pharma also climbed higher despite any news. It was momentum that kept the stock going after the company announced last week that it would be working with Pfizer.